HER2-targeted CAR-T for HER2-positive advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new immune-cell therapy (CAR-T) that targets a protein called HER2 in people with advanced or metastatic solid cancers. It may help shrink tumors and control the disease after standard treatments have failed or when there is no clear standard option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old, and you expect to live more than 3 months.
- You have an advanced/metastatic solid tumor that is HER2-positive (at least 30% HER2) and either has failed first-line treatment or has no standard first-line option.
- Your cancer has at least one measurable spot that doctors can track on scans.
- You can provide fresh tumor tissue (best) or stored tumor tissue from the last 6 months, and you agree to a possible new biopsy.
- You finished prior treatment at least 4 weeks ago and you have recovered to mild side effects (grade 1 or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This study tests a new type of immune cell therapy that seeks out and attacks cancer cells. It is for people with advanced solid tumors who have not improved with standard treatments and whose tumors show certain markers.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This phase 1 trial tests a new way to use your own immune cells to fight advanced solid tumors. The treatment is given directly into the tumor. It is for people who have run out of standard treatment options.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
Hear when a new HER2 Positive Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.